Dr. Paul Kenworthy, MD
What this data tells you about Dr. Kenworthy
Dr. Paul Kenworthy is an urology physician in Huntsville, TX, with 20 years in practice. Based on federal Medicare data, Dr. Kenworthy performed 5,522 Medicare services across 2,832 unique beneficiaries.
Between the years covered by Open Payments, Dr. Kenworthy received a total of $16,514 from 34 pharmaceutical and/or device companies across 148 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in urology physician. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Kenworthy is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Infectious disease DNA/RNA test | 1,132 | $34 | $71 |
| Automated urinalysis | 635 | $2 | $14 |
| Office visit, established patient (30-39 min) | 496 | $83 | $250 |
| Bladder ultrasound after voiding | 490 | $7 | $20 |
| Yeast/candida DNA test | 436 | $34 | $71 |
| Office visit, established patient (20-29 min) | 341 | $58 | $176 |
| Blood draw (venipuncture) | 284 | $8 | $12 |
| Urinalysis with microscopic exam | 254 | $3 | $18 |
| Detection test by nucleic acid for multiple organisms, amplified probe(s) technique | 154 | $69 | $140 |
| Diagnostic exam of bladder and urethra using an endoscope | 147 | $166 | $479 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 109 | $132 | $695 |
| New patient office visit (45-59 min) | 95 | $108 | $324 |
| Detection test by nucleic acid for staphylococcus aureus (bacteria), amplified probe technique | 88 | $34 | $72 |
| Detection test by nucleic acid for staphylococcus aureus, methicillin resistant (mrsa bacteria), amplified probe technique | 88 | $34 | $72 |
| Detection test by nucleic acid for strep (streptococcus, group b), amplified probe technique | 88 | $34 | $71 |
| Detection test by nucleic acid for strep (streptococcus, group a), amplified probe technique | 86 | $34 | $71 |
| New patient office visit (30-44 min) | 62 | $71 | $216 |
| Hospital follow-up visit, moderate complexity | 57 | $60 | $138 |
| Detection test by nucleic acid for vancomycin resistance strep (vre), amplified probe technique | 52 | $34 | $71 |
| Simple change of bladder tube | 51 | $67 | $190 |
| Ultrasound scan of pelvic region through rectum | 49 | $100 | $399 |
| Insertion of implant in urethra within prostate gland using an endoscope, each additional implant | 42 | $658 | $1,784 |
| Ceftriaxone antibiotic injection | 41 | $0 | $15 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 37 | $26 | $65 |
| Office visit, established patient (10-19 min) | 37 | $37 | $110 |
| Simple bladder irrigation and/or instillation | 32 | $54 | $150 |
| Initial hospital admission, moderate complexity | 29 | $99 | $261 |
| Simple insertion of temporary bladder tube | 27 | $43 | $122 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 27 | $15 | $45 |
| Hospital follow-up visit, high complexity | 21 | $91 | $198 |
| Insertion of implant in urethra within prostate gland using an endoscope, 1 implant | 12 | $967 | $2,595 |
| Biopsy of prostate gland | 12 | $148 | $478 |
| Initial hospital admission, high complexity | 11 | $110 | $383 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
The majority of payments (69%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in urology physician and does not inherently indicate bias, but patients may wish to be aware.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Kenworthy is a clinical cardiology specialist, with above-average Medicare volume (top 21% in TX), and high industry engagement (speaking/promotional, top 14%), with 20 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Kenworthy experienced with infectious disease dna/rna test?
Does Dr. Kenworthy receive payments from pharmaceutical companies?
How do Dr. Kenworthy's costs compare to other urology physicians in Huntsville?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology